AMAG Pharmaceuticals Inc. (AMAG)’s Financial Results Comparing With Compugen Ltd. (NASDAQ:CGEN)

We will be contrasting the differences between AMAG Pharmaceuticals Inc. (NASDAQ:AMAG) and Compugen Ltd. (NASDAQ:CGEN) as far as institutional ownership, profitability, risk, analyst recommendations, dividends, earnings and valuation are concerned. The two businesses are rivals in the Biotechnology industry.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
AMAG Pharmaceuticals Inc. 474.00M 1.16 169.34M -4.73 0.00
Compugen Ltd. 17.80M 11.89 22.51M -0.43 0.00

Demonstrates AMAG Pharmaceuticals Inc. and Compugen Ltd. earnings per share, top-line revenue and valuation.


Table 2 shows us the return on assets, return on equity and net margins of both businesses.

Net Margins Return on Equity Return on Assets
AMAG Pharmaceuticals Inc. -35.73% -5.3% -2.4%
Compugen Ltd. -126.46% -65.1% -50.1%

Risk & Volatility

AMAG Pharmaceuticals Inc.’s 0.23 beta indicates that its volatility is 77.00% less volatile than that of Standard & Poor’s 500. Competitively, Compugen Ltd. is 35.00% more volatile than Standard & Poor’s 500, because of the 1.35 beta.


The current Quick Ratio of AMAG Pharmaceuticals Inc. is 2.7 while its Current Ratio is 2.9. Meanwhile, Compugen Ltd. has a Current Ratio of 4.6 while its Quick Ratio is 4.6. Compugen Ltd. is better positioned to pay off its short-term and long-term debts than AMAG Pharmaceuticals Inc.

Analyst Recommendations

AMAG Pharmaceuticals Inc. and Compugen Ltd. Recommendations and Ratings are available on the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
AMAG Pharmaceuticals Inc. 1 0 0 1.00
Compugen Ltd. 0 0 0 0.00

AMAG Pharmaceuticals Inc. has a consensus target price of $18, and a 13.14% upside potential.

Institutional and Insider Ownership

AMAG Pharmaceuticals Inc. and Compugen Ltd. has shares owned by institutional investors as follows: 0% and 18.2%. Insiders owned roughly 1.8% of AMAG Pharmaceuticals Inc.’s shares. Comparatively, 12% are Compugen Ltd.’s share owned by insiders.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
AMAG Pharmaceuticals Inc. -1.22% -4.45% -26.78% -26.02% 26.45% 34.57%
Compugen Ltd. -7.23% -8.81% -19.75% -12.65% 28.4% 28.4%

For the past year AMAG Pharmaceuticals Inc.’s stock price has bigger growth than Compugen Ltd.


AMAG Pharmaceuticals Inc. beats on 7 of the 11 factors Compugen Ltd.

AMAG Pharmaceuticals, Inc., a biopharmaceutical company, manufactures, develops, and commercializes therapeutics for womenÂ’s health, anemia management, and cancer supportive care in the United States. It markets Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients with chronic kidney disease; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds. The company also offers Cord Blood Registry services that are related to the collection, processing, and storage of umbilical cord blood and cord tissue units for pregnant women and their families. In addition, it has a option agreement with Velo to acquire the rights to digoxin immune fab, a polyclonal antibody in clinical development for the treatment of severe preeclampsia in pregnant women. The company sells Feraheme to authorized wholesalers and specialty distributors. It has a license agreement with Palatin Technologies, Inc. to research, develop, and commercialize Rekynda, an investigational product designed to be an on-demand treatment for hypoactive sexual desire disorder in pre-menopausal women, as well as with Endoceutics, Inc. to develop and commercialize pharmaceutical products with dehydroepiandrosterone; and development and license agreement with Antares Pharma, Inc. to develop, use, sell, and offer for sale and import and export the Makena auto-injector. AMAG Pharmaceuticals, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.

Compugen Ltd., a therapeutic discovery company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel and Europe. The companyÂ’s pipeline primarily includes early and preclinical stage immuno-oncology programs based on novel drug targets, such as immune checkpoint and myeloid protein target candidates to harness the immune system to provide treatment solutions in the areas of unmet medical needs in various cancer types and patient populations. Its antibody drug conjugate target candidates comprise CGEN-15001T, CGEN-15022, CGEN-15029, and CGEN-15137 for oncology; and therapeutic proteins include CGEN-15001, a fusion protein for autoimmune diseases, as well as CGEN myeloid target. The company was incorporated in 1993 and is headquartered in Holon, Israel.